Meta-Analysis: Increased Physical Activity Decreases RCC Risk

Article

High levels of physical activity were linked with a 22% decreased risk for renal cancer, according to a meta-analysis that looked at results from 19 studies that quantified the relationship with physical activity and renal cancer.

High levels of physical activity were linked with a 22% decreased risk for renal cancer, according to a meta-analysis that looked at results from 19 studies that quantified the relationship with physical activity and renal cancer.

The results of the analysis were published in British Journal of Cancer.

“There are several plausible biologic mechanisms linking a high level of physical activity to reduced renal cancer risk,” said Gundula Behrens, PhD, of the department of epidemiology and preventive medicine at Regensburg University Medical Center, Regensburg, Germany. “Although it is speculative, physical activity may decrease renal cancer risk by reducing unfavorable conditions, such as adiposity, hypertension, insulin resistance, or oxidative stress, factors that are thought to be related to the development of renal cancer.”

Behrens and colleagues identified 19 relevant studies for the meta-analysis. These studies were inclusive of more than 2 million patients and more than 10,000 cases of renal cancer.

When the researchers used a random effects model to summarize the risk estimates for renal cancer from the 19 studies, results indicated that a high level of physical activity resulted in a relative risk for renal cancer of 0.88 (95% CI, 0.79–0.97). By isolating the risk summaries from just those studies deemed to be of high quality, the association between a high level of physical activity and a decreased risk for renal cancer increased (relative risk = 0.78; 95% CI, 0.66–0.92).

Further evaluation of the data revealed that the relative risk of the high-quality studies was not affected by factors such as the type of physical activity assessment, timing in life of physical activity, sex, study design or region, hypertension, smoking, obesity, or diabetes.

The researchers noted that the 19 studies had varying definitions of low and high physical activity, which may have affected the results. This variation meant that no specific “type, intensity, frequency, and duration of physical activity required to lower renal cancer risk” could be identified. Further research will be required to identify this information.

“Our study suggests that renal cancer can be added to the list of cancers potentially preventable by regular physical activity,” Behrens said.

Patients should be encouraged to engage in regular physical activity to reduce the risk of not only renal cancer, but cancer of other sites, such as the colon, breast, and endometrium, where a high level of physical activity has the potential to decrease the risk for cancer, according to Behrens.

Recent Videos
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Related Content